PNAA
AZN icon

Pictet North America Advisors’s AstraZeneca AZN Stock Holding History

Pictet North America Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.9M Buy
218,800
+1,864
+0.9% +$351K 3.61% 4
2026
Q1 		$42M Buy
216,936
+170,481
+367% +$32.9M 4.17% 3
2025
Q4 		$8.54M Sell
46,455
-3,706
-7% -$650K 0.81% 35
2025
Q3 		$7.7M Buy
50,161
+1,301
+3% +$197K 0.72% 38
2025
Q2 		$6.83M Sell
48,860
-137
-0.3% -$19.2K 0.69% 38
2025
Q1 		$7.2M Buy
48,997
+1,216
+3% +$176K 0.72% 38
2024
Q4 		$6.26M Buy
47,781
+32,568
+214% +$4.56M 0.6% 46
2024
Q3 		$2.37M Hold
15,213
– – 0.23% 72
2024
Q2 		$2.37M Sell
15,213
-16,154
-51% -$2.43M 0.26% 72
2024
Q1 		$4.25M Sell
31,367
-4,958
-14% -$657K 0.47% 48
2023
Q4 		$4.89M Sell
36,325
-3,335
-8% -$434K 0.63% 38
2023
Q3 		$5.37M Sell
39,660
-32,349
-45% -$4.42M 0.76% 36
2023
Q2 		$10.3M Sell
72,009
-3,278
-4% -$482K 1.43% 19
2023
Q1 		$10.5M Sell
75,287
-15,193
-17% -$2.04M 1.69% 18
2022
Q4 		$12.3M Sell
90,480
-3,145
-3% -$394K 2.11% 18
2022
Q3 		$10.3M Sell
93,625
-920
-1% -$117K 1.64% 21
2022
Q2 		$12.5M Sell
94,545
-4,277
-4% -$561K 1.65% 20
2022
Q1 		$13.1M Buy
98,822
+727
+0.7% +$87.2K 1.52% 21
2021
Q4 		$11.4M Sell
98,095
-1,126
-1% -$132K 1.12% 25
2021
Q3 		$11.9M Sell
99,221
-18,374
-16% -$2.14M 1.18% 28
2021
Q2 		$28.2M Buy
117,595
+1,371
+1% +$150K 2.91% 13
2021
Q1 		$23.2M Buy
116,224
+2,455
+2% +$247K 2.72% 14
2020
Q4 		$22.8M Buy
113,769
+1,314
+1% +$139K 2.89% 13
2020
Q3 		$24.6M Sell
112,455
-2,029
-2% -$226K 3.46% 11
2020
Q2 		$23.8M Sell
114,484
-1,362
-1% -$141K 3.42% 11
2020
Q1 		$20.7M Sell
115,846
-939
-0.8% -$88.4K 3.55% 10
2019
Q4 		$23.5M Buy
116,785
+679
+0.6% +$63.9K 2.89% 11
2019
Q3 		$20.8M Buy
116,106
+8,352
+8% +$724K 2.84% 12
2019
Q2 		$17.7M Sell
107,754
-12,733
-11% -$998K 2.57% 14
2019
Q1 		$19.3M Sell
120,487
-17,497
-13% -$1.38M 2.88% 12
2018
Q4 		$20.6M Sell
137,984
-2,041
-1% -$159K 1.87% 12
2018
Q3 		$21.8M Buy
140,025
+2,090
+2% +$158K 2.89% 12
2018
Q2 		$19.1M Sell
137,935
-1,282
-0.9% -$92.2K 2.85% 12
2018
Q1 		$19.1M Buy
139,217
+6,852
+5% +$475K 2.88% 9
2017
Q4 		$18.3M Sell
132,365
-960
-0.7% -$64.7K 2.82% 11
2017
Q3 		$17.7M Sell
133,325
-353
-0.3% -$22.3K 2.81% 12
2017
Q2 		$17.8M Buy
133,678
+270
+0.2% +$17.6K 2.96% 11
2017
Q1 		$16.4M Sell
133,408
-3,031
-2% -$176K 2.73% 12
2016
Q4 		$7.46M Sell
136,439
-7,350
-5% -$417K 1.64% 18
2016
Q3 		$9.45M Buy
143,789
+3,074
+2% +$201K 2.25% 15
2016
Q2 		$8.5M Buy
+140,715
New +$8.17M 1.98% 17

Other funds holding AZN

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
CDDEC
Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
BTCPP
Border to Coast Pensions Partnership Leeds, United Kingdom $6.78B AUM 31.6% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $2.92B AUM
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Pictet North America Advisors's AZN Position: Q2 2026 in Review

Pictet North America Advisors increased its AstraZeneca (AZN) stake by 0.86% in Q2 2026, buying an estimated $351K and bringing the position to 218,800 shares worth $40.9M. The position accounts for 3.61% of the portfolio, ranked #4.

Pictet North America Advisors first reported a position in AZN in Q2 2016 and has held it in 41 quarters since. The position peaked at $42M in Q1 2026. 655 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Pictet North America Advisors held 218,800 shares of AstraZeneca worth $40.9M as of Q2 2026.
  • Pictet North America Advisors bought 1,864 AstraZeneca shares in Q2 2026, an estimated $351K.
  • AstraZeneca made up 3.61% of Pictet North America Advisors's portfolio in Q2 2026, its #4 holding.
  • Pictet North America Advisors first reported a position in AstraZeneca in Q2 2016 and has held it in 41 quarters since.
  • Pictet North America Advisors's AstraZeneca position peaked at $42M in Q1 2026.
  • 655 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Pictet North America Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.